Last updated: April 24, 2026

Application No. 19/240,194

Untitled Application

Unknown

Filed

1600

Examiner

SOROUSH, LAYLA

Art Unit

1622

Tech Center

Azurity Pharmaceuticals, Inc.

Assignee

Azurity Pharmaceuticals, Inc.

OA Round

1 (Non-Final)

This examiner grants 40% of cases after interview

— +43.0% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 868 resolved cases, 2023–2026

Examiner Intelligence

SOROUSH, LAYLA View full profile →

Grants 40% of resolved cases

Career Allow Rate

349 granted / 868 resolved

-19.8% vs TC avg

Strong +43% interview lift

Without

With

+43.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 10m

Avg Prosecution

54 currently pending

Career history

922

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

50.3%

+10.3% vs TC avg

§102

12.5%

-27.5% vs TC avg

§112

12.9%

-27.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 868 resolved cases

Prosecution Timeline

1600

Application Filed

Feb 21, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

19/274,086

Patent 12564593

TOPICAL FORMULATION FOR A JAK INHIBITOR

2y 5m to grant Granted Mar 03, 2026

17/771,122

Patent 12544343

TREATMENT OF INFLAMMATORY CONDITION IN MUCOUS MEMBRANE OR SKIN

2y 5m to grant Granted Feb 10, 2026

19/171,214

Patent 12544381

TOPICAL FORMULATION FOR JAK INHIBITOR

2y 5m to grant Granted Feb 10, 2026

17/271,261

Patent 12527731

ACRYLATE-FREE COSMETIC EMULSION

2y 5m to grant Granted Jan 20, 2026

17/052,775

Patent 12522587

CANCER TREATMENTS TARGETING CANCER STEM CELLS

2y 5m to grant Granted Jan 13, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

40%

Grant Probability

83%

With Interview (+43.0%)

3y 10m

Median Time to Grant

Low

PTA Risk

Based on 868 resolved cases by this examiner. Grant probability derived from career allow rate.